Authors
Loading...
This research demonstrates FOXA1's role in ER+ breast cancer, revealing significant interactions with NR2C2, suggesting new therapeutic targets.
Plagens et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: